Apoptosis in Health and Disease - Part A
110,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Gebundenes Buch

Apoptosis, or programmed cell death, is the mechanism by which cells die either physiologically or pathologically. A vast research in apoptosis has advanced our understanding of basic physiological and pathological processes occurring in cells, organs and organisms, and its role in a number of diseases. These new advanced understandings are playing a major influence in drug discovery and the introduction of new therapies that target this cell death process. These two thematic volumes 125 and 126 of the Advances in Protein Chemistry and Structural Biology focus on apoptotic responses in…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Apoptosis, or programmed cell death, is the mechanism by which cells die either physiologically or pathologically. A vast research in apoptosis has advanced our understanding of basic physiological and pathological processes occurring in cells, organs and organisms, and its role in a number of diseases. These new advanced understandings are playing a major influence in drug discovery and the introduction of new therapies that target this cell death process. These two thematic volumes 125 and 126 of the Advances in Protein Chemistry and Structural Biology focus on apoptotic responses in numerous conditions - from bacterial and parasite infections to pathological states such as oxidative stress, pulmonary hypertension, different cancer types, etc. Finally, therapeutic strategies for targeting apoptosis are also discussed.
Autorenporträt
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other jo

urnals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.